Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group W-135 polysaccharide-tetanus toxoid conjugate vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The meningococcal group W-135 polysaccharide-tetanus toxoid conjugate vaccine is a specialized biologic developed by the Rijksinstituut voor Volksgezondheid en Milieu (RIVM) to prevent invasive meningococcal disease caused by *Neisseria meningitidis* serogroup W-135. The vaccine consists of the purified capsular polysaccharide of the W-135 serogroup covalently linked to a tetanus toxoid carrier protein. This conjugation process is critical as it converts the polysaccharide from a T-cell independent antigen into a T-cell dependent one, thereby significantly enhancing immunogenicity in infants and young children and inducing long-term immunological memory. This specific formulation was developed and utilized in the Netherlands, particularly in response to the epidemiological shift and rise in serogroup W cases observed in the mid-2010s.
- Other names
- Meningococcal W-135 conjugate vaccineMenW conjugate vaccine
02
Targets
MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal group W-135 polysaccharide-tetanus toxoid conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group W-135 polysaccharide-tetanus toxoid conjugate vaccine.